Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01268059 · ClinicalTrials.gov registry record · Phase 1
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT01268059 is a Phase 1 study that was terminated before completion, run by MedImmune. The registered enrollment target is 99 participants.
The verdict
NCT01268059, a Phase 1 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the dose, antitumor activity, safety and pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with previously untreated, advanced non-small cell lung cancer (NSCLC).
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG MEDI-575
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2010-12-16 |
| Est. Completion | 2013-09-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01268059
The ClinicalTrials.gov registry entry for NCT01268059 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT01268059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01268059 about?
NCT01268059 is a clinical study titled "A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer". The purpose of this study is to evaluate the dose, antitumor activity, safety and pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with previously untreated, advanced non-small cell lung cancer (NSCLC).
What is the current status of trial NCT01268059?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2010-12-16. Estimated completion is 2013-09-11.
What interventions are being tested in trial NCT01268059?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), MEDI-575 (DRUG).
Who is sponsoring clinical trial NCT01268059?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.